NEO-001

NEO-001 is an investigational high-dose psilocybin-based therapy being developed by NeonMind Biosciences as a pharmacologic intervention for obesity, administered together with structured behavioral therapy and lifestyle interventions. It is intended to leverage psilocybin’s serotonergic psychedelic effects to modulate appetite, eating behavior, and related neurocircuitry, while the accompanying behavioral program aims to consolidate durable weight-management habits. The company has completed a pre-IND consultation with the FDA outlining the clinical development path for NEO-001 in obesity and related metabolic indications, with plans to advance into formal clinical testing.